4D Molecular Therapeutics Completes Phase 3 Enrollment in 11 Months, Secures $33 Target
4D Molecular Therapeutics completed enrollment for its 4FRONT-1 Phase 3 trial of intravitreal 4D-150 in wet AMD patients in 11 months, comparing to aflibercept 2 mg with non-inferiority on visual acuity at 52 weeks. Barclays initiated coverage with an Overweight rating and $33 price target on January 27.
1. Phase 3 Enrollment Completion
On February 9, 4D Molecular Therapeutics confirmed full enrollment for its 4FRONT-1 trial evaluating 4D-150 in treatment-naïve wet age-related macular degeneration patients. The multicenter, randomized, double-masked study compares a single intravitreal dose of 4D-150 to aflibercept 2 mg, targeting non-inferiority in mean change from baseline in best-corrected visual acuity at 52 weeks.
2. Barclays Coverage and Price Target
On January 27, Barclays initiated coverage of 4D Molecular Therapeutics with an Overweight rating and set a $33 price target. The firm cited expected industry tailwinds from M&A activity, strong fundamentals, and reduced emphasis on drug pricing as drivers for biotech valuations in 2026.
3. Company Platform and Pipeline
4D Molecular Therapeutics is a clinical-stage genetic medicines company using its Therapeutic Vector Evolution platform to develop treatments for ophthalmology, pulmonology and cardiology. The firm currently advances five clinical-stage candidates and two preclinical assets, positioning 4D-150 as its lead program targeting the large wet AMD market.